Access360
The future of pharmaceutical and MedTech success in China demands more than a pricing-centered access framework—it requires an integrated strategy across insurance, medicine, and care delivery. That’s the driving force behind Access360.
Access360 fuses policy intelligence with executive learning to help global life sciences leaders anticipate—and act on—the forces reshaping China’s access landscape for innovative medicines.
Taking a true ecosystem view, it connects the dots across policy moves, funding pathways, and healthcare delivery shifts—equipping you with both a strategic compass and an essential tool for interpreting major policies and emerging trends.
With Access360, you’ll stay ahead of:
- Major policy shifts reshaping China's drug pricing frameworks.
- The growing integration between basic medical insurance (BMI) and commercial health insurance (CHI)—fueling insurance product innovation and new partnership models between manufacturers and insurers.
- The evolving landscape of payment innovations transforming how care—and new therapies—are financed in China.
- Provider reforms, care delivery innovations, and digital infrastructure shifts that will either accelerate or impede access to innovative medicines.
In a market moving this fast, Access360 is built to keep you one step ahead.
